Impact of inotropic therapy on mortality in cardiogenic shock following acute myocardial infarction

• DOI: 10.1093/ehjacc/zuaf044.044
• Publication Date: 2025-04-23T11:07:48Z
• Authors: A Bakalli; R Lila; E Bajrami; E Limani; A Osa; S Avdiu; X Krasniqi; D Zijabeg; A Ferati; V Mahmutaj; L Keka; L Bashota; A Krasniqi; S Elezi; A Krasniqi

Abstract Introduction Cardiogenic shock (CS) complicates 3-13% of acute myocardial infarction (AMI) cases, with a mortality rate approximately 40% within the first 30 days, making it leading cause death in AMI patients. accounts for 81% CS cases. Pharmacological therapies, including inotropic agents vasoactive and vasopressor effects, are commonly administered these Purpose This study aimed to examine relationship between therapy patients post-AMI their outcomes. Methods We conducted prospective cross-sectional from March 20 October 20, 2024. Patients admitted coronary syndrome (STEMI or NSTEMI) were evaluated, those who developed included study. Participants categorized into two groups based on outcomes: group survival group. Results Among 1,166 at Clinic Cardiology over seven-month period, 86 (7.4%) CS. Of these, 44 (51%) died. Table 1 compares respect administered. Significant differences observed number used, 52% survivors receiving only one agent, compared 20.5% (p=0.002). Additionally, received noradrenaline more frequently higher doses predominantly group, as shown 1. Variables statistical significance multiple regression model (Table 2a), which showed (p=0.02), indicating that than doses, risk mortality. Noradrenaline dose was identified an independent predictor 2b). Conclusions In our center, 7% develop CS, nearly half resulting death. single agent have chance, whereas noradrenaline, especially elevated may reflect trend treating critically ill aggressive could indicate effect treatment itself. Larger studies needed clarify this finding.